Could nighttime chemo hours ease cancer care? survey seeks patient views
NCT ID NCT07483905
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses an anonymous online survey to ask 200 women with gynecologic cancers whether they would be interested in receiving long chemotherapy infusions at night instead of during the day. The goal is to understand patient preferences and potential barriers. No treatment is given—this is purely a fact-finding survey to help hospitals decide if nighttime services would be useful.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If patients show strong interest, hospitals may offer nighttime chemotherapy hours, making long infusions more convenient for daily life.
- What could go wrong
- This is only a survey, not a treatment trial. Patient interest may not translate into real-world feasibility or improved outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female patients * aged 18 years or older * Diagnosis of a gynecologic cancer * Receiving care at the participating institution * Ability to independently understand and complete complete the anonymous online survey Exclusion Criteria: * Inability to access or complete the online questionnaire or difficulty with reading and writing * Cognitive impairment * Patients currently hospitalized or in emergency settings.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gynecologic cancers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI chatbot may sharpen nurses' cancer care decisions
- A simple drain may slash wound infections after gynecologic cancer surgery
- New digital tool aims to boost fertility awareness in cancer patients
- Rare surgery for recurrent cancer: how does it affect quality of life?
- BRCA study aims to unlock cancer secrets
- New combo aims to fix chemo side effect in cancer survivors